Skip to content
2000
Volume 28, Issue 24
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Prostate cancer is the fifth cause of tumor-related deaths in man worldwide. Due to its long latency period, this pathology represents an ideal type of disease for chemopreventive studies. Among the drugs considered thus far for the treatment of prostate cancer, the natural compound resveratrol emerged as very promising. Resveratrol is widely recognized as a chemopreventive agent and was shown to potentiate the antitumor activity of conventional chemotherapeutics in several tumors, including prostate cancer. Here, we overview the literature of the last five years and summarize the recent achievements of resveratrol and its derivatives as antimetastatic agents in prostate cancer. Moreover, drug combination studies as well as nanomedicine approaches proposed to improve resveratrol activity and to overcome delivery drawbacks are addressed. The last part of the review discusses the clinical trials containing resveratrol ongoing on cancer patients.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867328666201228124038
2021-07-01
2025-04-15
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867328666201228124038
Loading

  • Article Type:
    Review Article
Keyword(s): clinical trials; drug combination; metastasis; Prostate cancer; resveratrol; stilbenoids
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test